Table 3 Genes differentially expressed in common among colon cancer cell lines resistant to MTX
From: Networking of differentially expressed genes in human cancer cells resistant to methotrexate
GenBank ID | Gene name | Description | Ratio HT29 | Ratio Caco-2 |
|---|---|---|---|---|
AI144299 | DHFR | Dihydrofolate reductase | 7.25 | 46.35 |
BC005238 | FXYD3 | FXYD domain containing ion transport regulator 3 | 7.24 | 2.20 |
BC003584 | DHFR | Dihydrofolate reductase | 6.96 | 50.23 |
BC000192 | DHFR | Dihydrofolate reductase | 6.89 | 38.31 |
NM_002380 | MATN2 | Matrilin 2 | 6.62 | 4.70 |
BU078629 | ZFYVE16 | Zinc finger, FYVE domain containing 16 | 6.06 | 22.73 |
NM_001975 | ENO2 | Enolase 2 (gamma, neuronal) | 5.98 | 2.04 |
NM_017954 | CADPS2 | Ca2+-dependent activator protein for secretion 2 | 5.60 | 2.27 |
AI991103 | AXIIR | Similar to annexin II receptor | 5.14 | 2.03 |
NM_000791 | DHFR | Dihydrofolate reductase | 4.71 | 21.17 |
U05598 | AKR1C2 | Aldo-keto reductase family 1, member C2 | 4.63 | 10.15 |
M33376 | AKR1C2 | Aldo-keto reductase family 1, member C2 | 4.41 | 8.89 |
NM_012242 | DKK1 | Dickkopf homolog 1 | 4.25 | 2.56 |
NM_014867 | KBTBD11 | Kelch repeat and BTB (POZ) domain containing 11 | 4.22 | 2.14 |
AB037848 | KIAA1427 | Synaptotagmin XIII | 4.13 | 9.56 |
NM_014733 | ZFYVE16 | Zinc finger, FYVE domain containing 16 | 4.11 | 15.6 |
NM_001353 | AKR1C1 | Aldo-keto reductase family 1, member C1 | 3.94 | 8.87 |
NM_002439 | MSH3 | MutS homolog 3 | 3.87 | 4.00 |
S68290 | AKR1C1 | Aldo-keto reductase family 1, member C1 | 3.66 | 9.45 |
J04810 | MSH3 | MutS homolog 3 | 3.27 | 8.23 |
NM_000691 | ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | 2.86 | 3.81 |
AI718385 | SLC26A2 | Solute carrier family 26 member 2 | 2.76 | 2.02 |
NM_003069 | SMARCA1 | SWI/SNF related, regulator of chromatin a1 | 2.60 | 2.49 |
AB029026 | TACC1 | Transforming, acidic coiled-coil containing protein 1 | 2.35 | 3.89 |
NM_006283 | TACC1 | Transforming, acidic coiled-coil containing protein 1 | 2.31 | 3.26 |
AF188298 | DAB2 | Disabled homolog 2 | 2.29 | 2.11 |
NM_020299 | AKR1B10 | Aldo-keto reductase family 1, member B10 | 2.26 | 22.95 |
BC006471 | MLLT11 | Myeloid/lymphoid or mixed-lineage leukemia | 2.18 | 2.60 |
W93554 | SH3PXD2A | SH3 and PX domains 2A | 2.14 | 3.45 |
NM_014778 | NUPL1 | Nucleoporin like 1 | 0.46 | 0.43 |
NM_006033 | LIPG | Lipase, endothelial | 0.40 | 0.42 |
NM_012338 | TM4SF12 | Transmembrane 4 superfamily member 12 | 0.39 | 0.38 |
NM_007150 | ZNF185 | Zinc finger protein 185 (LIM domain) | 0.38 | 0.42 |
AB014605 | MAGI2 | Membrane associated guanylate kinase | 0.38 | 0.30 |
AB033831 | SCDGF | Platelet derived growth factor C | 0.35 | 0.35 |
NM_021021 | SNTB1 | Syntrophin, beta 1 | 0.35 | 0.23 |
NM_021822 | APOBEC3G | Apolipoprotein B, catalytic polypeptide-like 3G | 0.30 | 0.08 |
AB039791 | ARP11 | Actin-related protein Arp11 | 0.29 | 0.46 |
NM_013352 | SART2 | Squamous cell carcinoma antigen | 0.22 | 0.31 |
NM_004362 | CLGN | Calmegin | 0.21 | 0.19 |
AI912583 | GLIPR1 | GLI pathogenesis-related 1 (glioma) | 0.21 | 0.45 |
Z19574 | KRT17 | Keratin 17 | 0.19 | 0.46 |
NM_003186 | TAGLN1 | Transgelin | 0.19 | 0.14 |
NM_014059 | RGC32 | Response gene to complement 32 | 0.17 | 0.44 |
BE872674 | CLEC3A | C-type lectin domain family 3, member A | 0.15 | 0.24 |
NM_003212 | TDGF1/3 | Teratocarcinoma-derived growth factor 1/3 | 0.13 | 0.47 |
BC000069 | RARRES2 | Retinoic acid receptor responder 2 | 0.07 | 0.33 |
AF110400 | FGF19 | Fibroblast growth factor 19 | 0.06 | 0.26 |
NM_006851 | GLIPR1 | GLI pathogenesis-related 1 | 0.05 | 0.28 |
NM_006169 | NNMT | Nicotinamide N-methyltransferase | 0.04 | 0.24 |
AF208043 | IFI16 | Interferon, gamma-inducible protein 16 | 0.03 | 0.38 |
BG256677 | IFI16 | Interferon, gamma-inducible protein 16 | 0.02 | 0.40 |
NM_006169 | NNMT | Nicotinamide N-methyltransferase | 0.02 | 0.24 |